Cancer Stem Cells Market Size was valued at USD 2.1 Bn in 2023 and is predicted to reach USD 4.5 Bn by 2031 at a 9.7% CAGR during the forecast period for 2024-2031.
The Cancer stem cells Industry is a product of the global business community’s fixation with cancer stem cells, a subpopulation of tumours, and their possible therapeutic targets. Cancer cells ' abilities to self-renew and differentiate impact tumor progression, growth, and treatment resistance. The cancer stem cell market is growing because cancer stem cells are essential for tumour development, progression, and recurrence; the rising global cancer incidence is a key factor propelling the cancer stem cell market. Furthermore, Cancer stem cells market expansions are being driven by the development of novel therapies, which in turn are being supported by rising investments in cancer research initiatives from governments, private organizations, and pharmaceutical companies, as well as by continuously improving research technologies like 3D organoid models and single-cell sequencing is market fueling expansion.
However, Cancer stem cells market growth is hampered by the strict regulatory criteria of cancer stem cells, and creating therapy, researching, and developing strategies to target cancer stem cells is a time-consuming and expensive endeavor. In addition, because of the growing consensus among regulatory bodies regarding the therapeutic value of cancer stem cell targeting, promising medications are being expedited through the review and approval processes, which is driving the market growth. Furthermore, factors driving market expansion include an uptick in cancer cases and fatalities globally and a surge in research and development efforts related to the creation of these medications. Cancer stem cell therapy is in high demand because the incidence of cancer is on the rise worldwide.
Competitive Landscape
Some of the Cancer Stem Cells Market Players are:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- STEMCELL Technologies Inc.
- Sino Biological Inc.
- Celgene Corporation
- AbbVie Inc.
- Incyte Corporation
- Novartis AG
- Pfizer Inc.
- Bionique Testing Laboratories Inc.
- Miltenyi Biotec GmbH
- Lonza Group AG
- OncoMed Pharmaceuticals Inc.
- Daiichi Sankyo Company Limited
- Verastem Inc.
- Others
Market Segmentation:
The cancer stem cells market is segmented based on cancer type, treatment type, biomarker type, and end-user. Based on cancer type, the market is segmented into breast cancer, lung cancer, brain cancer, prostate cancer, colorectal cancer, and others. By treatment type, the market is segmented into chemotherapy, immunotherapy, targeted therapy, stem cell transplantation, and others. By biomarker type, the market is segmented into CD44, CD133, ALDH1, and others. By end-user, the market is segmented into hospitals, cancer research institutes, biotechnology companies, and academic research institutes.
Breast Cancer segment is Accounted as a Major Contributor to the Cancer Stem Cell Market
The breast cancer segment is expected to hold a major global market share in 2023 because of a growing number of cases of breast cancer around the world and the critical requirement for novel, efficient treatments. Recent studies on cancer stem cells have shed light on their function in breast cancer treatment-related issues, such as medication resistance and recurrence. More and more research is being conducted to find ways to target breast cancer stem cells as people become more aware of these dynamics.
Cancer Research Institutes Segment to Witnessed Growth at a Rapid Rate
Cancer research institutes are growing rapidly in the cancer stem cells market due to a heightened commitment to understanding the causes of cancer and a concentrated effort to combat them, together with increasing finances. These centers aim to enhance patient outcomes and decrease recurrence rates through the use of innovative medicines that target cancer stem cells precisely.
North American Region Holds a Significant Revenue Share in Cancer Stem Cells Market
The North American cancer stem cells market is expected to register the highest market share in revenue in the near future. It can be attributed to the focus on establishing targeted treatments and precision oncology tactics that are adapted to individual patient profiles, a heavy emphasis on personalized medicine approaches, state-of-the-art research facilities, and partnerships between universities and biotech firms to speed up the development of cancer stem cell research and treatments. In addition, Asia Pacific is projected to grow rapidly in the global cancer stem cells market because of the large population and increasing demand for high-quality healthcare in the region, as well as the growing number of people who are becoming more health-conscious and in need of cutting-edge medical technology.
Recent Developments:
- In April 2024, STEMCELL Technologies is proud to announce that the U.S. Food and Drug Administration officially classified their innovative EasySepTM Human Bone Marrow CD138 Positive Selection Kit as a groundbreaking in vitro diagnostic medical device for hematopoietic cell enrichment.
- In March 2024, Merck, a frontrunner in the scientific and technological industries, introduced the world to the first comprehensive, laboratory-validated genetic stability test. Accelerating biosafety assessment and the transition into commercial production, the AptegraTM CHO genetic stability assay utilizes whole genome sequencing and bioinformatics.
Cancer Stem Cells Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.1 Bn |
|
Revenue Forecast In 2031 |
USD 4.5 Bn |
|
Growth Rate CAGR |
CAGR of 9.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Cancer Type, By Treatment Type, By Biomarker Type, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Thermo Fisher Scientific Inc., Merck KGaA, STEMCELL Technologies Inc., Sino Biological Inc., Celgene Corporation, AbbVie Inc., Incyte Corporation, Novartis AG, Pfizer Inc., Bionique Testing Laboratories Inc., Miltenyi Biotec GmbH, Lonza Group AG, OncoMed Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Verastem Inc., and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
